MCID: OVR094
MIFTS: 41

Ovarian Epithelial Cancer

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 54 30 6
Epithelial Ovarian Cancer 54 74
Ovarian Epithelial Carcinoma 54
Ovarian Cancer, Epithelial 54
Eoc 54

Classifications:



External Ids:

UMLS 74 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to adenocarcinoma and ovarian cancer. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and bone.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.2 H19 MALAT1 PIK3CA
2 ovarian cancer 29.7 H19 HAGLR HOTAIR MALAT1 MEG3 PIK3CA
3 retinoblastoma 29.5 HOTAIR MALAT1 MEG3
4 endometrial cancer 28.9 H19 HOTAIR MEG3 PIK3CA
5 melanoma 28.7 H19 HOTAIR MALAT1 MEG3
6 lung cancer susceptibility 3 28.5 H19 HOTAIR MALAT1 MEG3 PIK3CA
7 lung cancer 28.4 H19 HAGLR HOTAIR MALAT1 MEG3 PIK3CA
8 esophageal cancer 28.0 H19 HOTAIR HULC MALAT1 MEG3 PIK3CA
9 ovarian clear cell carcinoma 11.5
10 ovary transitional cell carcinoma 11.2
11 thrombocytosis 10.3
12 ovarian cyst 10.3
13 ovarian cancer 1 10.3
14 fallopian tube carcinoma 10.2
15 pancreatic neuroendocrine tumor 10.2 MEG3 PIK3CA
16 body mass index quantitative trait locus 1 10.2
17 sclerosing cholangitis, neonatal 10.1
18 primary peritoneal carcinoma 10.1
19 respiratory system cancer 10.1 MALAT1 PIK3CA
20 breast cancer 10.1
21 insulin-like growth factor i 10.1
22 wilms tumor 5 10.1
23 wilms tumor 6 10.1
24 leukemia 10.1
25 endometriosis of ovary 10.1
26 vulva squamous cell carcinoma 10.1 MALAT1 MEG3
27 meningioma, radiation-induced 10.0 H19 MEG3
28 blood group, colton system 10.0
29 wiskott-aldrich syndrome 10.0
30 headache associated with sexual activity 10.0
31 diabetes mellitus 10.0
32 chlamydia 10.0
33 patulous eustachian tube 10.0
34 clear cell adenocarcinoma 10.0
35 depression 10.0
36 silver-russell syndrome 10.0 H19 MEG3
37 tongue squamous cell carcinoma 10.0 MALAT1 MEG3
38 functionless pituitary adenoma 9.9 HOTAIR MEG3
39 esophagus squamous cell carcinoma 9.9 HOTAIR MEG3
40 triple-receptor negative breast cancer 9.9 HOTAIR MALAT1
41 choriocarcinoma 9.9 H19 MALAT1
42 multiple sclerosis 9.8
43 migraine with or without aura 1 9.8
44 polykaryocytosis inducer 9.8
45 thrombophilia due to thrombin defect 9.8
46 down syndrome 9.8
47 suppressor of tumorigenicity 3 9.8
48 wilms tumor 1 9.8
49 enterocolitis 9.8
50 hemochromatosis, type 1 9.8

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 703)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Peppermint Approved Phase 4
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Ferrous fumarate Approved Phase 4,Early Phase 1,Not Applicable 141-01-5
9
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 114977-28-5 148124
10
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
12
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
15
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
16
Iron Approved, Experimental Phase 4,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
17
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 54670067 5785
18
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-18-4 6057
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2455)
# Name Status NCT ID Phase Drugs
1 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
5 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
6 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
7 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
8 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
9 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
10 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
12 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
15 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
16 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
17 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
18 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
19 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
20 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
21 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
22 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
23 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
24 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
25 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
26 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
27 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
28 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
29 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
30 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
31 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
32 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
33 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
34 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
35 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
36 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
37 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
38 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
39 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
40 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
41 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
42 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
43 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
44 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
45 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
46 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
47 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3 amifostine trihydrate
48 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
49 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
50 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 30

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

42
T Cells, Testes, Bone, Ovary, Breast, Bone Marrow, Prostate

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 3091)
# Title Authors Year
1
Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer. ( 30675307 )
2019
2
Long noncoding RNA TP73-AS1 accelerates the epithelial ovarian cancer via epigenetically repressing p21. ( 31105851 )
2019
3
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. ( 31105878 )
2019
4
Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis. ( 31108164 )
2019
5
Epithelial ovarian cancer stem‑like cells are resistant to the cellular lysis of cytokine‑induced killer cells via HIF1A‑mediated downregulation of ICAM‑1. ( 31059002 )
2019
6
M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. ( 31062668 )
2019
7
Tripartite Motif-Containing Protein 59 (TRIM59) Promotes Epithelial Ovarian Cancer Progression via the Focal Adhesion Kinase(FAK)/AKT/Matrix Metalloproteinase (MMP) Pathway. ( 31062766 )
2019
8
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. ( 31074244 )
2019
9
Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. ( 31074247 )
2019
10
Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. ( 30944645 )
2019
11
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study. ( 30851097 )
2019
12
Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer. ( 30854089 )
2019
13
Platelet-derived growth factor-D expression mediates the effect of differentiated degree on prognosis in epithelial ovarian cancer. ( 30652340 )
2019
14
Analysis of the inhibitory effects of miR-124 and miR-152 on human epithelial ovarian cancer xenografts in a nude mouse model. ( 30655773 )
2019
15
Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis. ( 30661076 )
2019
16
Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). ( 30661922 )
2019
17
Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography. ( 30630889 )
2019
18
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. ( 29718305 )
2019
19
The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. ( 29922900 )
2019
20
Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based nontargeted and targeted analyses. ( 30114318 )
2019
21
Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. ( 30168853 )
2019
22
Association of lymphadenectomy and survival in epithelial ovarian cancer. ( 30149960 )
2019
23
Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery? ( 30316718 )
2019
24
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review. ( 30304728 )
2019
25
Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort. ( 30287910 )
2019
26
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. ( 30451713 )
2019
27
Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. ( 30518816 )
2019
28
Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff? ( 30479095 )
2019
29
Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. ( 30463683 )
2019
30
MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. ( 30557834 )
2019
31
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. ( 30640700 )
2019
32
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. ( 30632888 )
2019
33
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. ( 30617925 )
2019
34
Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. ( 30614075 )
2019
35
Low-grade epithelial ovarian cancer: what a radiologist should know. ( 30604635 )
2019
36
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer. ( 30591474 )
2019
37
Long noncoding RNA SNHG15 serves as an oncogene and predicts poor prognosis in epithelial ovarian cancer. ( 30588034 )
2019
38
Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. ( 30713783 )
2019
39
Potential of osteopontin in the management of epithelial ovarian cancer. ( 30712025 )
2019
40
A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility. ( 30709872 )
2019
41
Is peritonectomy and hyperthermic intraperitoneal chemotherapy a new standard of treatment for advanced epithelial ovarian cancer? ( 30706448 )
2019
42
Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. ( 30704745 )
2019
43
Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. ( 30698271 )
2019
44
Preferences of women with epithelial ovarian cancer for aspects of genetic testing. ( 30693090 )
2019
45
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. ( 30691488 )
2019
46
Breastfeeding factors and risk of epithelial ovarian cancer. ( 30686553 )
2019
47
Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. ( 30683677 )
2019
48
Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer. ( 30672383 )
2019
49
Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. ( 30796833 )
2019
50
MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research. ( 30795761 )
2019

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
5 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
6 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Ovarian Epithelial Cancer

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....